178 related articles for article (PubMed ID: 21622091)
1. Src-family tyrosine kinases as therapeutic targets in advanced cancer.
Gelman IH
Front Biosci (Elite Ed); 2011 Jun; 3(3):801-7. PubMed ID: 21622091
[TBL] [Abstract][Full Text] [Related]
2. The role of Src in solid tumors.
Wheeler DL; Iida M; Dunn EF
Oncologist; 2009 Jul; 14(7):667-78. PubMed ID: 19581523
[TBL] [Abstract][Full Text] [Related]
3. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
Zhang S; Yu D
Trends Pharmacol Sci; 2012 Mar; 33(3):122-8. PubMed ID: 22153719
[TBL] [Abstract][Full Text] [Related]
4. Src signaling pathways in prostate cancer.
Varkaris A; Katsiampoura AD; Araujo JC; Gallick GE; Corn PG
Cancer Metastasis Rev; 2014 Sep; 33(2-3):595-606. PubMed ID: 24522479
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of Src expression and activity in human neoplasia.
Chatzizacharias NA; Kouraklis GP; Giaginis CT; Theocharis SE
Histol Histopathol; 2012 Jun; 27(6):677-92. PubMed ID: 22473690
[TBL] [Abstract][Full Text] [Related]
7. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders.
Benati D; Baldari CT
Curr Med Chem; 2008; 15(12):1154-65. PubMed ID: 18473810
[TBL] [Abstract][Full Text] [Related]
8. [SRC kinases in tumor therapy].
Dempke W; Zippel R
Med Klin (Munich); 2010 Oct; 105(10):711-5. PubMed ID: 20981590
[TBL] [Abstract][Full Text] [Related]
9. Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets.
Bußmann L; Hoffer K; von Bargen CM; Droste C; Lange T; Kemmling J; Schröder-Schwarz J; Vu AT; Akingunsade L; Nollau P; Rangarajan S; de Wijn R; Oetting A; Müller C; Böckelmann LC; Zech HB; Berger JC; Möckelmann N; Busch CJ; Böttcher A; Gatzemeier F; Klinghammer K; Simnica D; Binder M; Struve N; Rieckmann T; Schumacher U; Clauditz TS; Betz CS; Petersen C; Rothkamm K; Münscher A; Kriegs M
Int J Cancer; 2021 Sep; 149(5):1166-1180. PubMed ID: 33890294
[TBL] [Abstract][Full Text] [Related]
10. SRC inhibitors as potential therapeutic agents for human cancers.
Trevino JG; Summy JM; Gallick GE
Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
[TBL] [Abstract][Full Text] [Related]
11. Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors.
Filippi I; Naldini A; Carraro F
Curr Med Chem; 2011; 18(19):2885-92. PubMed ID: 21651491
[TBL] [Abstract][Full Text] [Related]
12. Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer.
Gelman IH; Peresie J; Eng KH; Foster BA
Mol Cancer Res; 2014 Oct; 12(10):1470-9. PubMed ID: 25053806
[TBL] [Abstract][Full Text] [Related]
13. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.
Laird AD; Li G; Moss KG; Blake RA; Broome MA; Cherrington JM; Mendel DB
Mol Cancer Ther; 2003 May; 2(5):461-9. PubMed ID: 12748308
[TBL] [Abstract][Full Text] [Related]
14. Src and focal adhesion kinase as therapeutic targets in cancer.
Brunton VG; Frame MC
Curr Opin Pharmacol; 2008 Aug; 8(4):427-32. PubMed ID: 18625340
[TBL] [Abstract][Full Text] [Related]
15. Src family kinases differentially influence glioma growth and motility.
Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
[TBL] [Abstract][Full Text] [Related]
16. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.
Johnson FM; Gallick GE
Anticancer Agents Med Chem; 2007 Nov; 7(6):651-9. PubMed ID: 18045060
[TBL] [Abstract][Full Text] [Related]
17. [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
Klener P; Klener P
Klin Onkol; 2010; 23(4):203-9. PubMed ID: 20806817
[TBL] [Abstract][Full Text] [Related]
18. Src inhibitors in breast cancer therapy.
Hiscox S; Nicholson RI
Expert Opin Ther Targets; 2008 Jun; 12(6):757-67. PubMed ID: 18479222
[TBL] [Abstract][Full Text] [Related]
19. Allosteric networks governing regulation and catalysis of Src-family protein tyrosine kinases: implications for disease-associated kinases.
Cheng HC; Johnson TM; Mills RD; Chong YP; Chan KC; Culvenor JG
Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):93-101. PubMed ID: 19566834
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of Src family kinases and therapeutic implications of their modulators.
Kumar A; Jaggi AS; Singh N
Fundam Clin Pharmacol; 2015 Apr; 29(2):115-30. PubMed ID: 25545125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
